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Abstract: We present a case of a chronic mass-forming pancreatitis (CMFP) detected by 18F-choline
(FCH) PET/CT in a male affected by prostate cancer. FCH PET/CT scan showed a focal uptake in the
uncinate process of the pancreas, later diagnosed as a CMFP at biopsy. Although the physiological
distribution of FCH in the pancreas, a careful interpretation of the images in this area is warranted.
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Figure 1. A male patient with prostate cancer underwent 18F-Choline (FCH) PET/CT for the
suspicion of lymph node recurrence during hormonal therapy. He was not submitted to local
therapies (i.e., surgery or radiotherapy) for the treatment of the primary prostate lesion. The patient
has, in addition, a history of diabetes mellitus type II and hypertensio . PET/CT detected multiple
areas of focal FCH uptakes ((A); maximum intensity projection—MIP) in prostate gland (arrow,
(B)) and abdominal-pelvic lymphadenopathies (arrows, (C)), compatible with recurrent prostate
cancer. Moreover, a focal tracer uptake was shown in the uncinate process of the pancreas with a
maximum standardized uptake value (SUVmax) equal to 13.6 (arrow, (D)). As already stated by
Schillaci et al. [1], FCH may physiologically show a moderate-to-high uptake in the liver and the
pancreas. However, the presence of a focal uptake should be further investigated in order to make a
Diagnostics 2021, 11, 1490. https://doi.org/10.3390/diagnostics11081490 https://www.mdpi.com/journal/diagnostics
Diagnostics 2021, 11, 1490 2 of 3
differential diagnosis with a malignant or benign lesion. A subsequent MRI showed no definite lesion
but rather a slight “mass-like” enlargement of the pancreatic head, as visible on the axial single-shot
turbo-spin echo T2-weighted image (arrow, (E)). Some micro-cystic areas were appreciated in the
pancreaticoduodenal groove (arrowhead, (E)). The absence of lesions was confirmed on the post-
contrast pancreatic phase (axial gradient echo volumetric fat saturated image), in which pancreatic
parenchyma appears homogeneous, with no solid tissue extending towards major vascular structures
(arrowhead, (F)). Of note, the cholangiopancreatography sequence showed a normal-sized but
irregular main pancreatic duct, with no cephalic structures (arrow, (G)). Overall, subtle morphological
changes and ductal abnormalities supported the diagnosis of CMFP. The Carbohydrate antigen 19–9
(CA19.9) was normal (17.0 UI/mL). However, after one month from MRI and FCH PET/CT, the
patient was submitted to an endoscopic ultrasound (EUS) exam and biopsy, based on the suggestion
of the multidisciplinary team.










































Figure 2. The histological examination demonstrated fragments of sclerotic stroma in storiform
fashion, in which inflammation cells (most lymphocyte and plasma cells) were recognizable ((A–C);
Hematoxylin and Eosin tains differe t magnificat o s). Moreover, the immunostaining for CD38
highlighted the plasma cells population (D) and immunostaining for IgG4 showed a considerable
amount of specific immunoglobulin in diagnostic range for type 1 autoimmune pancreatitis (E). The
CMFP represents the 10–30% of chronic pancreatitis and the differential diagnosis with pancreatic
cancer is very difficult [2]. MRI has a high diagnostic accuracy in the diagnosis of chronic pancreatitis
with a sensitivity and specificity, respectively, of 78% and 96% [3]. Gu et al. suggest using 18F-FDG
PET/CT combined with CA19–9 to differentially diagnose pancreatic cancer from CMFP [4]. EUS
is a very sensitive examination to detect pancreatic masses and can provide useful information in
cases where conventional radiologic workup remains inconclusive [5]. Thanks to its high-resolution
i ages, EUS is more precise than MRI and CT for the diagnosis of small pancreatic lesions. However,
its specificity remains low (about 50%) since most lesions showe unclear echoic signs. Probably, the
association of EUS with contrast enhancement and elastography can increase the overall accuracy [6,7].
Choline plays an important role in the structure and the function of biological membranes and is
esse tial for the synthesis of phospholipids [8]. The distribution of FCH is physiological in the
pancreas as in the liver, spleen, salivary, and lacrimal glands [1]. The uptake of choline is also present
in many cancers and in the immune cells as macrophages, present in inflammatory processes [9–11].
This is the first case of CMFP detected by FCH. We cannot recommend the use of FCH PET as an
alternative diagnostic imaging in autoimmune pancreatic processes, but we strongly suggest careful
interpreting PET-imaging (especially in case of focal tracer uptake in the pancreas). Furthermore,
images from hybrid PET/MRI scanners [8] should be assessed, since they can provide complete
information by using a single examination.
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